New CellCelector CLD takes you from thousands of candidates to the top clone, faster. 

Sartorius announces the launch of the CellCelector CLD, an automated imaging and cell isolation platform designed to simplify and accelerate monoclonal cell line development (CLD). 

It combines high-speed scanning, advanced imaging, and gentle clone retrieval, enabling scientists to rapidly identify, verify, and isolate the most promising clones, while maintaining viability and ensuring reliable documentation. 

According to Towards Healthcare, the cell isolation and analysis products market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 20.91 billion in 2026 to approximately USD 57.05 billion by 2035, representing a compound annual growth rate (CAGR) of 11.8% from 2026 to 2035. Growth is driven by the rise in biologic drugs and the need for advanced cell isolation techniques for therapeutic cell manufacturing, with a focus on developing high-throughput technologies that minimise contamination and improve purity levels. 

A profile of Sartorius: 

It is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes.  

The CellCelector CLD is part of Sartorius’ broader cell line development ecosystem, bringing together instruments, consumables, reagents, and media into a single, cohesive workflow. For bioprocess teams under pressure to move faster, reduce costs, and meet regulatory standards, it represents a meaningful step forward in the capabilities of automated CLD. 

Product Manager of CellCelector Systems at Sartorius, Darius Wilson, said what used to take months can now be completed in approximately seven weeks. The CellCelector CLD gives teams the confidence to move from screening to stable, high-producing cell lines faster than standard workflows, with full traceability at every step. 

A recent report by Towards Healthcare highlights that the cell isolation and analysis products market is witnessing growth driven by advancements in cell biology research, regenerative medicine, and biopharmaceutical production, and the adoption of automation, microfluidics, and AI-powered tools is expected to improve isolation efficiency. 

North America is experiencing a growing demand for personalised medicine and regenerative therapies. This demand is driven by the increasing prevalence of chronic diseases like cancer and diabetes, which necessitate the isolation of specific cell types for research and development.  

Asia-Pacific is the fastest-growing market for cell isolation and analysis products, driven by the increasing prevalence of chronic diseases, the need for advanced treatment modalities, and the rising focus on personalised medicine.